Immune-related adverse events associated with immune checkpoint inhibitors for advanced gastric and gastroesophageal junction cancer: A meta-analysis

作者：Wen-Guang Pei, Wen-Zheng Chen, Yukang Wu, Shengxing Tan, Zhigang Jie · 发表于：World Journal of Gastrointestinal Oncology · 年份：2023 · DOI：10.4251/wjgo.v15.i2.352 · 被引用次数：4 · 研究领域：Cancer Immunotherapy and Biomarkers、Inflammatory Biomarkers in Disease Prognosis、Gastric Cancer Management and Outcomes

BACKGROUND: Immune checkpoint inhibitors (ICIs) have shown promising efficacy in treatment and clinical management of advanced gastric and gastroesophageal junction cancer. However, the inhibitors also cause immune-related adverse events (irAEs). The current systematic review and meta-analysis study aimed to investigate the incidence and nature of irAEs caused by ICIs. AIM: To investigate the incidence and nature of irAEs in advanced gastric and gastroesophageal junction cancer. METHODS: This systematic review was registered with PROSPERO (Reg. number: CRD42020152291). Data included in this study were collected from patients diagnosed with advanced gastric cancer or gastroesophageal junction cancer and treated with ICIs. A systematic literature search was conducted using the PubMed, EMBASE, and Cochrane Library databases. Meta-analysis was carried out using the single sample rate method. Synthesis and analysis of the data was conducted using Stata/SE and Review Manager Software. RESULTS: The patients enrolled in the present study included 14 patients from 14 case reports, 326 patients from 6 case series, and 1249 patients from 8 clinical trials. It was found that the overall incidence of irAEs was 16% [95% confidence interval (CI): 11-20] for all grades and 3% (95%CI: 2-4) for the severe grade. It was evident that the incidence of irAEs varied with the type of inhibitor and organs. A comparative study of the anti-programmed cell death receptor-1 (PD-1) and anti-programmed dea...